Research·October 19, 2026 at 11:01 AM EDT·1 source
EyePoint's Phase 3 failure; Lilly's China drug delivery deal
LLY -2.5%
LLY · last 30 trading days+1.3% since the news
News
What happened
- EyePoint’s experimental drug failed in Phase 3, according to Endpoints News.
- The Watertown, Massachusetts-based biotech is eliminating 53% of its positions.
- The report also covers Lilly’s China drug-delivery deal, Longwood’s next fund and Ryzumvi’s label expansion, without further details in the source.
EyePoint positions eliminated
53%
Why it matters
The developments matter to healthcare investors and biotech professionals because they affect EyePoint’s workforce and pipeline outlook, while Lilly’s China drug-delivery activity may signal partnership activity in the sector.
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
Timeline
- EarlierOct 19Here are Monday's biggest analyst calls: SpaceX, Nvidia, Apple, CoreWeave, Amazon, Meta, Eli Lilly & more
- First reported by Endpoints NewsOct 19EyePoint's Phase 3 failure; Lilly's China drug delivery deal
Who is involved
EyePoint's Phase 3 failure; Lilly's China drug delivery dealEyePoint PharmaceuticalsEli LillyLLYLongwoodRyzumvi
CompanyInvestor
Sources (1)
- Endpoints NewsOct 19EyePoint's Phase 3 failure; Lilly's China drug delivery deal
Related
- Yesterday · #ESMO26: AstraZeneca eyes Keytruda's Padcev spot; Lilly's ADC takes on Elahere; Nubeqa targets earlier prostate cancer
- Oct 19 · Here are Monday's biggest analyst calls: SpaceX, Nvidia, Apple, CoreWeave, Amazon, Meta, Eli Lilly & more
- Oct 22 · Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020
- Oct 22 · Abu Dhabi lures Eli Lilly, Oura, and Whoop in healthcare push
- Oct 21 · Lilly’s retatrutide creeps closer to market for sleep apnea
- Oct 20 · STAT+: A bipartisan group of lawmakers urges the FDA to close a peptide loophole
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
- Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
- Follow developing storiesAn alert, and a push, the moment a story you follow moves.
- Your briefing, read aloudA few minutes each morning with a chapter per story.
- Brief modeSwipe through the day, a 20-second card each.